Online Abstracts Clinical Sciences - Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults B5 Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults



Invasive Pneumococcal Disease (IPD) is a cause of morbidity and mortality in children. Some Streptococcus pneumoniae isolates are resistant to antibiotics used for IPD, such as beta-lactams and macrolides. Increased resistance has been reported in Colombia.


Ambispective case series study in pediatric patients with IPD admitted in 10 hospitals of Bogotá in 2008-2019, and 4 hospitals of Cali, 2 of Medellin and 1 of Cartagena in 2017-2019 (preliminary data).


651 cases of IPD were found. Susceptibility profile information was obtained for 567(87%) isolates; 494(75.8%) were non-meningeal (NM) and 73(11.2%) meningeal (M). Regarding NM, 16.3% were penicillin-resistant, and 5.8% showed intermediate susceptibility; 5% were resistant to ceftriaxone and 9.5% had intermediate susceptibility. M showed 19.1% resistance to penicillin, 5.4% resistance to ceftriaxone, and 5.4% intermediate susceptibility. Resistance to macrolides was 26.2%, to clindamycin 19.7%, and trimethoprim sulfa 32%. All isolates were susceptible to vancomycin. Only 23.8% of the isolates were susceptible to all antibiotics; 36% were multi-resistant. The serotype most resistant to penicillin was 19A (26.8%), which was associated with multi-resistance.


An increase in antibiotic resistance is observed in relation to previous reports associated with emergence of multiresistant S. pneumoniae serotype 19A.